Abstract 2351P
Background
Cancer in adolescents and young adults (AYAs, aged 18-39 years at first cancer diagnosis) is nowadays considered as a separate entity with specific care needs. However, once the diagnosis has been established, AYA patients are mostly treated as having cancer at an older age. Breakthroughs in treatment options are scarce and AYA patients are underrepresented in clinical trials. To improve healthcare outcomes, there is a large unmet need for obtaining more knowledge and better (genomic) understanding of cancers at AYA age.
Methods
As an independent not-for-profit cancer diagnostics organization and data provider, Hartwig Medical Foundation performs clinical-grade whole genome sequencing (WGS) for cancer patients using a single small fresh-frozen biopsy and a matching blood sample. In addition to comprehensive diagnostic reporting of oncology-related genomics aberrations (including mutations, copy-number alterations, fusions and mutational signatures like MSI, TMB, HRD) all WGS data is (following patient consent) stored in the Hartwig Database. This data (>5500 patients) is available to the academic community to facilitate research and improve future cancer patient care.
Results
The Hartwig Database currently includes WGS and associated clinical data for 192 metastatic AYA cancer patients. Although a fair number in total, the numbers per tumor indication are quite small with n > 30 for only three indications (breast n=49, bone/soft tissue n=33 and GI-tract n=34). Also, the distribution does not follow the AYA cancer type prevalence as registered in the Dutch national cancer registry, with e.g. GI-tract (18% vs 9%) and bone/soft tissue (17% vs 2%) overrepresented and male/female reproductive organs underrepresented (8 vs 18%). Preliminary analysis of the frequency of driver alterations of some of the well-known oncogenes (e.g. PIK3CA, BRAF, KRAS, ERBB2) do not reveal differences between AYA and non-AYA cancers although the low number of AYA samples hamper conclusiveness.
Conclusions
To better facilitate research for AYA patients and to offer all possible treatment options (e.g. clinical trials), more patients will need to be analyzed by WGS. For this purpose, a dedicated project has been initiated that includes tumor-normal WGS of 1000 AYA patients in the next 3 years.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16